

ARCA biopharma, Inc.  
Form 8-K  
January 20, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 20, 2010**

**ARCA biopharma, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000-22873**  
**(Commission File Number)**

**8001 Arista Place, Suite 200, Broomfield, CO 80021**

**36-3855489**  
**(I.R.S. Employer**  
  
**Identification No.)**

**Edgar Filing: ARCA biopharma, Inc. - Form 8-K**

**(Address of Principal Executive Offices) (Zip Code)**

**(720) 940-2200**

**(Registrant's Telephone Number, Including Area Code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On January 20, 2010, ARCA biopharma, Inc. issued a press release announcing that the paper "An Alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal *Circulation: Heart Failure*. The press release is attached as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

**Exhibit  
No.**

**Description**

99.1	Press Release titled "ARCA announces publication of bucindolol data in <i>Circulation: Heart Failure</i> ", dated January 20, 2010.
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 20, 2010

**ARCA biopharma, Inc.**

(Registrant)

By: /s/ MICHAEL R. BRISTOW  
Name: **Michael R. Bristow**  
Title: **President and Chief Executive Officer**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release titled ARCA announces publication of bucindolol data in <i>Circulation: Heart Failure</i> , dated January 20, 2010.